US firm Cortendo has signed an exclusive licence agreement with Australia-based Antisense Therapeutics to develop and commercialise ATL1103 for endocrinology applications.

ATL1103 is an Antisense’s second-generation antisense drug that is being designed to block growth hormone receptor (GHr) expression to reduce levels of the hormone insulin-like growth factor-1 (IGF-1) in the blood.

It is said to be a potential treatment for diseases associated with excessive growth hormone and IGF-1 action, including acromegaly, diabetic retinopathy and diabetic nephropathy.

"The opportunity to advance ATL1103 nicely complements COR-003, our existing Phase III asset for Cushing’s syndrome, and builds upon our rare endocrine disease franchise."

Cortendo president and CEO Matthew Pauls said: "The opportunity to advance ATL1103, a novel second-generation antisense therapeutic with potential utility in acromegaly, nicely complements COR-003, our existing Phase III asset for Cushing’s syndrome, and builds upon our rare endocrine disease franchise."

As part of the deal, Cortendo will pay an initial upfront payment of $5m to Antisense, including $3m in cash and $2m as equity investment in Antisense.

The deal will also include additional payments of up to $105m based on achieving specific development and commercialisation milestones. In addition, Antisense will receive royalty payments based on sales achievement.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Cortendo will take the responsibility for the ongoing clinical development of ATL1103 in endocrinology applications, in addition to funding the associated future development, regulatory and drug manufacture costs.

The deal will allow Antisense to retain commercialisation rights for ATL1103 in endocrinology applications in Australia and New Zealand, as well as rights for other ATL1103 indications worldwide.